Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit

被引:83
作者
De Haan, L
Verweij, WR
Feil, IK
Holtrop, M
Hol, WGJ
Agsteribbe, E
Wilschut, J [1 ]
机构
[1] Univ Groningen, GUIDE, Dept Physiol Chem, Groningen, Netherlands
[2] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA
[5] Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA
关键词
D O I
10.1046/j.1365-2567.1998.00535.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Escherichia coli (E. coli) heat-labile toxin (LT) is a potent mucosal immunogen and immunoadjuvant towards co-administered antigens. LT is composed of one copy of the A subunit, which has ADP-ribosylation activity, and a homopentamer of B subunits, which has affinity for the toxin receptor, the ganglioside G(M1). Both the ADP-ribosylation activity of LTA and G(M1) binding of LTB have been proposed to be involved in immune stimulation. We investigated the roles of these activities in the immunogenicity of recombinant LT or LTB upon intranasal immunization of mice using LT/LTB mutants, lacking either ADP-ribosylation activity, G(M1)-binding affinity, or both. Likewise, the adjuvant properties of these LT/LTB variants towards influenza virus subunit antigen were investigated. With respect to the immunogenicity of LT and LTB, we found that G(M1)-binding activity is essential for effective induction of anti-LTB antibodies. On the other hand, an LT mutant lacking ADP-ribosylation activity retained the immunogenic properties of the native toxin, indicating that ADP ribosylation is not critically involved. Whereas adjuvanticity of LTB was found to be directly related to G(M1)-binding activity, adjuvanticity of LT was found to be independent of G(M1)-binding affinity. Moreover, a mutant lacking both G(M1)-binding and ADP-ribosylation activity, also retained adjuvanticity. These results demonstrate that neither ADP-ribosylation activity nor G(M1) binding are essential for adjuvanticity of LT, and suggest an ADP-ribosylation-independent adjuvant effect of the A subunit.
引用
收藏
页码:424 / 430
页数:7
相关论文
共 33 条
[1]   ADJUVANT ACTIVITY OF ESCHERICHIA-COLI HEAT-LABILE ENTERO-TOXIN AND EFFECT ON THE INDUCTION OF ORAL TOLERANCE IN MICE TO UNRELATED PROTEIN ANTIGENS [J].
CLEMENTS, JD ;
HARTZOG, NM ;
LYON, FL .
VACCINE, 1988, 6 (03) :269-277
[2]  
de Haan L, 1998, STP PHARMA SCI, V8, P75
[3]   Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin [J].
DeHaan, L ;
Verweij, WR ;
Feil, IK ;
Lijnema, TH ;
Hol, WGJ ;
Agsteribbe, E ;
Wilschut, J .
INFECTION AND IMMUNITY, 1996, 64 (12) :5413-5416
[4]   Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: Role of the A subunit [J].
deHaan, L ;
Holtrop, M ;
Verweij, WR ;
Agsteribbe, E ;
Wilschut, J .
VACCINE, 1996, 14 (04) :260-266
[5]   REDUCTION IN ORAL IMMUNOGENICITY OF CHOLERA TOXIN-B SUBUNIT BY N-TERMINAL PEPTIDE ADDITION [J].
DERTZBAUGH, MT ;
ELSON, CO .
INFECTION AND IMMUNITY, 1993, 61 (02) :384-390
[6]   DISSOCIATION OF ESCHERICHIA-COLI HEAT-LABILE ENTEROTOXIN ADJUVANTICITY FROM ADP-RIBOSYLTRANSFERASE ACTIVITY [J].
DICKINSON, BL ;
CLEMENTS, JD .
INFECTION AND IMMUNITY, 1995, 63 (05) :1617-1623
[7]   Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of Hsai-Labile enterotoxin as a mucosal adjuvant [J].
DiTommaso, A ;
Saletti, G ;
Pizza, M ;
Rappuoli, R ;
Dougan, G ;
Abrignani, S ;
Douce, G ;
DeMagistris, M .
INFECTION AND IMMUNITY, 1996, 64 (03) :974-979
[8]   MUTANTS OF ESCHERICHIA-COLI HEAT-LABILE TOXIN LACKING ADP-RIBOSYLTRANSFERASE ACTIVITY ACT AS NONTOXIC, MUCOSAL ADJUVANTS [J].
DOUCE, G ;
TURCOTTE, C ;
CROPLEY, I ;
ROBERTS, M ;
PIZZA, M ;
DOMENGHINI, M ;
RAPPUOLI, R ;
DOUGAN, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1644-1648
[9]  
ELSON CO, 1984, J IMMUNOL, V133, P2892
[10]  
ELSON CO, 1984, J IMMUNOL, V132, P2736